{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T02:59:27Z","timestamp":1789009167555,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005689","name":"G\u00f6teborgs L\u00e4kares\u00e4llskap","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005689","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005009","name":"Stiftelsen Assar Gabrielssons Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012538","name":"Swedish Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012538","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004348","name":"Stockholms L\u00e4ns Landsting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.bbmt.2019.05.038","type":"journal-article","created":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T12:08:35Z","timestamp":1559822915000},"page":"1770-1778","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Secondary Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation in a Population-Based Setting"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0695-0050","authenticated-orcid":false,"given":"Christer","family":"Nilsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Huleg\u00e5rdh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2553-7659","authenticated-orcid":false,"given":"Hege","family":"Garelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"M\u00f6llg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Brune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Wahlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stig","family":"Lenhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulla","family":"Fr\u00f6din","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Remberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"H\u00f6glund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Juliusson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dick","family":"Stockelberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f6ren","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2019.05.038_bib0001","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.bbmt.2017.10.019","article-title":"Impact of allogeneic stem cell transplantation in first complete remission in acute myeloid leukemia: a national population-based cohort study","volume":"24","author":"\u00d8stg\u00e5rd","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.05.038_bib0002","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1200\/JCO.2013.50.5768","article-title":"Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis","volume":"32","author":"Stelljes","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2019.05.038_bib0003","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/jama.2009.813","article-title":"Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials","volume":"301","author":"Koreth","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.bbmt.2019.05.038_bib0004","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrclinonc.2012.150","article-title":"The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach","volume":"9","author":"Cornelissen","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bbmt.2019.05.038_bib0005","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.23908","article-title":"Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry","volume":"90","author":"Huleg\u00e5rdh","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2019.05.038_bib0006","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","article-title":"Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study","volume":"33","author":"Granfeldt \u00d8stgard","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2019.05.038_bib0007","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.05.038_bib0008","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.2009.21.8073","article-title":"Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia","volume":"28","author":"Lim","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2019.05.038_bib0009","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1182\/blood-2009-10-249128","article-title":"Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia","volume":"115","author":"Litzow","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.05.038_bib0010","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.bbmt.2018.04.008","article-title":"Transplant outcomes for secondary acute myeloid leukemia: acute leukemia working party of the European Society for Blood and Bone Marrow Transplantation Study","volume":"24","author":"Sengsayadeth","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.05.038_bib0011","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1200\/JCO.2000.18.5.963","article-title":"Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients. Report of the French Society of Bone Marrow Transplantation","volume":"18","author":"Yakoub-Agha","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2019.05.038_bib0012","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1182\/blood-2011-12-379008","article-title":"Acute myeloid leukemia in the real world: why population-based registries are needed","volume":"119","author":"Juliusson","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.05.038_bib0013","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.05.038_bib0014","unstructured":"Svensk F\u00f6rening f\u00f6r Hematologi. Akut myeloisk leukemi (AML)\u2013nationellt v\u00e5rdprogram. [The Swedish AML Group. Swedish national AML care program for adult patients], 2016. Available at: http:\/\/www.sfhem.se\/nyheter\/nationellt-vardprogram-aml [in Swedish]. Accessed April 22, 2019."},{"key":"10.1016\/j.bbmt.2019.05.038_bib0015","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.05.038_bib0016","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.bbmt.2019.05.038_bib0017","unstructured":"Gerds TA.prodlim: Product-limit estimation for censored event history analysis. R package version 1.6.1. 2017. Available at: https:\/\/rdrr.io\/cran\/prodlim\/. Accessed April 22, 2019."},{"key":"10.1016\/j.bbmt.2019.05.038_bib0018","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.3324\/haematol.2013.100784","article-title":"Survival analysis in hematologic malignancies: recommendations for clinicians","volume":"99","author":"Delgado","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2019.05.038_bib0019","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/tri.13081","article-title":"An unjustified benefit: immortal time bias in the analysis of time-dependent events","volume":"31","author":"Gleiss","year":"2018","journal-title":"Transplant Int"},{"key":"10.1016\/j.bbmt.2019.05.038_bib0020","unstructured":"Therneau TM.A package for survival analysis in S. Version 2.38. 2015. Available at: https:\/\/cran.r-project.org\/web\/packages\/survival\/index.html. Accessed April 22, 2019."},{"key":"10.1016\/j.bbmt.2019.05.038_bib0021","doi-asserted-by":"crossref","DOI":"10.18637\/jss.v042.i08","article-title":"MatchIt: nonparametric preprocessing for parametric causal inference","volume":"42","author":"Ho","year":"2011","journal-title":"J Stat Softw"},{"key":"10.1016\/j.bbmt.2019.05.038_bib0022","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.bbmt.2019.05.038_bib0023","unstructured":"Gray B.cmprsk: Subdistribution analysis of competing risks. R package version 2.2-7. 2014. Available at: https:\/\/www.r-project.org\/. Accessed April 22, 2019."},{"key":"10.1016\/j.bbmt.2019.05.038_bib0024","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2017."},{"key":"10.1016\/j.bbmt.2019.05.038_bib0025","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/bmt.2011.110","article-title":"The EBMT risk score","volume":"47","author":"Gratwohl","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.05.038_bib0026","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.05.038_bib0027","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jclinepi.2003.12.008","article-title":"Time-dependent bias was common in survival analyses published in leading clinical journals","volume":"57","author":"van Walraven","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.bbmt.2019.05.038_bib0028","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1200\/JCO.2011.40.5977","article-title":"Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission","volume":"31","author":"Burnett","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2019.05.038_bib0029","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/bmt.2015.151","article-title":"Outcomes of patients with therapy-related AML\/myelodysplastic syndrome (t-AML\/MDS) following hematopoietic cell transplantation","volume":"50","author":"Alam","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.05.038_bib0030","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/bmt.2015.338","article-title":"Long-term follow-up of therapy-related myelodysplasia and AML patients treated with allogeneic hematopoietic cell transplantation","volume":"51","author":"Finke","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.05.038_bib0031","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/bmt.2015.59","article-title":"Comparable outcomes post-allogeneic hematopoietic cell transplant for patients with de novo or secondary acute myeloid leukemia in first remission","volume":"50","author":"Michelis","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.05.038_bib0032","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.05.038_bib0033","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood-2016-12-754796","article-title":"Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation","volume":"129","author":"Yoshizato","year":"2017","journal-title":"Blood"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879119303635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879119303635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:07:03Z","timestamp":1761059223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879119303635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S1083879119303635"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2019.05.038","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Secondary Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation in a Population-Based Setting","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2019.05.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}